E-Prescribing Market Summary

• The E-Prescribing market size is estimated at USD 3.28 billion in 2025 and is projected to reach USD 9.65 billion by 2034. Growth is anchored in federal and state mandates for the electronic prescribing of controlled substances, near-universal electronic health record adoption, and the migration of price transparency, prior authorization, and medication management into the digital prescribing workflow.
• The global E-Prescribing market is growing at a CAGR of 12.7% during the forecast period from 2026 to 2034.
• By product, the integrated e-prescribing systems segment dominated the E-Prescribing market with a 68% share in 2025.
• By delivery mode, the cloud-based segment dominated the E-Prescribing market with a share of 74% in 2025.
• By usage, the non-controlled substance e-prescribing segment dominated the E-Prescribing market with a share of 81% in 2025.
• By end-user, the office-based physicians segment dominated the E-Prescribing market with a share of 46% in 2025.
• North America dominated the global E-Prescribing market revenue with a share of 48% in 2025, representing the highest regional market share globally.

E-Prescribing, also known as electronic prescribing or e-prescribing, refers to the computer-based generation, transmission, and management of prescriptions directly from a prescriber to a pharmacy through a secure electronic network, replacing handwritten and faxed orders. A complete e-prescribing solution combines prescriber-facing software, either embedded within an electronic health record or offered as a standalone application, with clinical decision support, formulary and benefit checks, medication history, and a routing network that connects physicians, pharmacies, pharmacy benefit managers, and health plans. The workflow spans prescription creation, drug interaction and allergy screening, real-time prescription benefit and prior authorization checks, secure transmission, and renewal management, and it increasingly incorporates the electronic prescribing of controlled substances (EPCS) with two-factor authentication. Over the past decade, e-prescribing has moved from an optional efficiency tool into essential clinical infrastructure, propelled by the HITECH Act, meaningful use incentives, the opioid crisis response, and federal and state EPCS mandates, so that it now underpins medication safety, adherence, and cost transparency across ambulatory, hospital, and specialty pharmacy care.

E-Prescribing Market Key Growth Drivers

• Federal and state EPCS mandates are accelerating adoption, with the SUPPORT for Patients and Communities Act requiring electronic prescribing of Schedule II to V controlled substances under Medicare Part D from January 2021 and the Centers for Medicare and Medicaid Services enforcing a 70% compliance threshold from January 2023.
• E-prescribing use continues to scale, with 1.39 million active prescribers on the Surescripts network in 2025, a 4.0% increase over 2024, and 84.4% of e-prescribers enabled for the electronic prescribing of controlled substances.
• Near-universal electronic health record adoption is embedding e-prescribing into routine clinical workflows, with 98% of e-prescribers served by EHR-enabled systems in 2025.
• Rising demand for medication safety is a catalyst, with the World Health Organization estimating that medication errors cost USD 42 billion globally each year, much of it preventable through electronic prescribing and clinical decision support.
• Real-time prescription benefit and price transparency tools are expanding, with 1 billion real-time prescription benefit transactions delivered in 2025, helping prescribers and patients identify lower-cost therapies at the point of care.
• Growth in specialty medications and electronic prior authorization is deepening platform value, with 28.4 million specialty prescriptions routed and a 19.9% increase in electronically processed prior authorizations in 2025.
• The convergence of regulatory mandates, EHR interoperability, medication safety imperatives, and value-added transparency and prior authorization services is expected to sustain double-digit growth in the global E-Prescribing market through 2034.

Key Companies in E-Prescribing Market

The competitive landscape is led by the following active software vendors, network operators, and solution providers:

• Surescripts, LLC
• Veradigm Inc.
• Oracle Corporation (Oracle Health)
• Epic Systems Corporation
• athenahealth, Inc.
• NextGen Healthcare, Inc.
• DrFirst, Inc.
• eClinicalWorks, LLC
• RxNT
• CureMD Healthcare, and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

E-Prescribing Market Size

The following snapshot summarizes the principal report metrics for the E-Prescribing market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the E-Prescribing Market

E-Prescribing Market Drivers

• Federal and State EPCS Mandates Driving Controlled-Substance E-Prescribing: Regulatory mandates are the single most powerful catalyst for e-prescribing adoption in the United States. The SUPPORT for Patients and Communities Act of 2018 required the electronic prescribing of Schedule II to V controlled substances under Medicare Part D beginning January 1, 2021, and the Centers for Medicare and Medicaid Services began enforcement on January 1, 2023, requiring prescribers to transmit at least 70% of qualifying controlled-substance claims electronically. Compliance actions for prescriptions written for beneficiaries in long-term care facilities took effect on January 1, 2025. These federal requirements are reinforced by a growing patchwork of state EPCS mandates that already cover the majority of the population. The combined effect has been a rapid rise in EPCS enablement, with 84.4% of e-prescribers and 98.3% of pharmacies enabled for controlled-substance e-prescribing in 2025, per Surescripts. As mandates broaden across payers and care settings, prescribers are compelled to upgrade software, adopt two-factor authentication, and integrate prescription drug monitoring program data, sustaining durable demand for compliant e-prescribing platforms across the forecast period.
• Rising Medication Errors and the Patient-Safety Imperative: The persistent burden of preventable medication errors continues to drive adoption of electronic prescribing and clinical decision support. The World Health Organization, through its Medication Without Harm initiative, estimates that the global cost associated with medication errors is USD 42 billion annually, and identifies unsafe medication practices as a leading cause of avoidable harm in health systems worldwide. Handwritten and verbal orders remain a significant source of transcription, dosing, and drug-interaction errors. Electronic prescribing mitigates these risks through legible standardized orders, automated allergy and drug-drug interaction screening, dose range checking, and medication reconciliation. Health systems and payers increasingly view e-prescribing as core patient-safety infrastructure rather than an administrative convenience, embedding it within quality and value-based care programs. As accreditation bodies and regulators tighten expectations for medication safety, the demand for decision-support-rich e-prescribing solutions is expected to expand across hospital, ambulatory, and long-term care settings, reinforcing sustained market growth through 2034.
• Near-Universal EHR Adoption and Interoperability: The widespread adoption of certified electronic health records has embedded e-prescribing into everyday clinical practice. In 2025, 98% of e-prescribers were served by EHR-enabled systems and the Surescripts network supported 1.39 million active prescribers, a 4.0% increase over the prior year. As office-based physicians and hospitals standardize on integrated EHR platforms, e-prescribing functionality is delivered natively within the clinical workflow, lowering the barrier to routine use. Interoperability initiatives, including nationwide health information exchange frameworks and standardized medication data, are further strengthening the value proposition by enabling comprehensive medication histories, accurate reconciliation, and coordinated care across providers and pharmacies. The maturation of application programming interfaces and cloud architectures allows independent practices and digital health entrants to embed prescribing capabilities rapidly. This deep integration between EHRs and e-prescribing networks creates a durable installed base and recurring transaction volume, positioning e-prescribing as essential digital infrastructure and supporting continued market expansion over the forecast period.
• Expansion of Real-Time Prescription Benefit and Price Transparency: Rising drug costs and patient affordability concerns are driving demand for price transparency at the point of prescribing. Real-time prescription benefit tools deliver patient-specific out-of-pocket cost and coverage information directly within the prescribing workflow, enabling clinicians to select lower-cost, covered alternatives before the prescription reaches the pharmacy. In 2025, 1 billion real-time prescription benefit transactions were delivered across the Surescripts network, contributing to significant patient savings, with average savings identified per prescription when lower-cost alternatives were available. These capabilities reduce prescription abandonment, improve adherence, and strengthen the clinical and commercial value of e-prescribing platforms. Payers, pharmacy benefit managers, and health systems increasingly require price transparency functionality as a standard component of prescribing, and vendors are differentiating on the breadth and accuracy of benefit data. As affordability remains a central policy and consumer concern, the integration of transparency services is expected to accelerate platform adoption and deepen recurring transaction revenue throughout the forecast period.
• Growth of Specialty Medications and Electronic Prior Authorization: The rapid growth of specialty medications is expanding the scope and value of e-prescribing platforms. Specialty drugs, which treat complex chronic conditions and account for a rising share of pharmacy spend, require intensive prior authorization, benefit verification, and coordination among prescribers, pharmacies, and payers. In 2025, 28.4 million specialty prescriptions were routed through the Surescripts network, and electronically processed prior authorizations rose 19.9%, with a 26.1% increase for specialty medications specifically. Electronic prior authorization automates a historically manual and time-consuming process, reducing therapy delays and administrative burden, with automated approvals delivered in a median of 18 seconds for supported medications in leading deployments. Vendors are investing heavily in prior authorization automation and specialty medication management to capture this high-value workflow. As specialty pipelines expand and payers intensify utilization management, e-prescribing platforms that integrate electronic prior authorization and specialty coordination are positioned to capture a growing share of prescribing activity, reinforcing market growth through 2034.
• Opioid Crisis Response and Prescription Drug Monitoring Integration: The public health response to the opioid epidemic continues to reinforce e-prescribing adoption. Electronic prescribing of controlled substances, combined with integration to state prescription drug monitoring programs, provides prescribers with real-time visibility into a patient's controlled-substance history, supporting safer prescribing and reducing diversion and doctor shopping. Federal and state policymakers have prioritized EPCS as a core tool for curbing inappropriate opioid prescribing, embedding it within broader substance-use and pain-management initiatives. The tight coupling of EPCS workflows with monitoring program queries, identity proofing, and two-factor authentication has elevated the compliance and security requirements of prescribing platforms. As opioid stewardship remains a national priority and monitoring program integration becomes standard, demand for secure, compliant controlled-substance e-prescribing is expected to remain strong, encouraging providers to adopt and upgrade platforms that meet evolving regulatory and clinical expectations across the forecast period.
• Digital Health Expansion, Telehealth, and Value-Added Services: The expansion of telehealth and digital-first care models is broadening the addressable market for e-prescribing. Virtual visits require remote, secure prescribing capabilities, and digital health companies increasingly embed e-prescribing through cloud platforms and application programming interfaces. Beyond core transmission, vendors are layering value-added services, including patient medication adherence messaging, price transparency, electronic prior authorization, and artificial-intelligence-driven workflow automation, that increase per-prescription value and platform stickiness. Recent industry activity underscores this shift, with providers deploying artificial intelligence to automate a majority of prior authorizations and next-generation patient engagement tools to lift adherence. This convergence of telehealth, cloud delivery, and intelligent medication management is enlarging the market beyond traditional office-based prescribing into pharmacies, specialty channels, and consumer-facing digital health, supporting sustained double-digit growth and creating differentiated competitive opportunities through 2034.

E-Prescribing Market Restraints

Despite strong regulatory tailwinds, the E-Prescribing market faces material constraints. Regulatory and compliance complexity is significant, as controlled-substance prescribing must satisfy Drug Enforcement Administration identity-proofing and two-factor authentication requirements, state-specific EPCS mandates, and evolving privacy and security rules, lengthening implementation timelines and raising compliance costs. Integration and interoperability challenges persist, since e-prescribing depends on seamless connectivity among heterogeneous electronic health records, pharmacy systems, pharmacy benefit managers, and monitoring programs, and incomplete or inconsistent data can undermine benefit checks and medication reconciliation. Upfront and ongoing costs, including software licensing, EHR integration, identity-proofing tokens, and staff training, remain barriers for small independent practices and resource-limited settings. Workflow disruption and clinician burden are recurring concerns, as poorly designed interfaces, alert fatigue from decision-support prompts, and additional authentication steps can slow prescribing and generate resistance. Reliance on a concentrated network layer for prescription routing introduces systemic and continuity-of-service risk, and periodic disruptions across connected clearinghouses and claims infrastructure have highlighted the exposure of the broader prescribing ecosystem. Cybersecurity and patient-privacy threats are acute given the sensitivity of medication and identity data, requiring continuous investment in safeguards. Uneven adoption outside the United States, driven by differing regulations, reimbursement, and digital infrastructure, limits the pace of global expansion, while inconsistent prescription drug monitoring program integration and data-standardization gaps constrain the full clinical value of controlled-substance e-prescribing in some jurisdictions.

E-Prescribing Market Segment Analysis

The E-Prescribing Market is segmented by product (integrated e-prescribing systems, standalone e-prescribing systems), delivery mode (cloud-based, on-premise), usage (non-controlled substance e-prescribing, controlled substance e-prescribing), end-user (office-based physicians, hospitals, pharmacies, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Integrated E-Prescribing Systems.

The integrated e-prescribing systems segment accounted for 68% of the E-Prescribing market in 2025. Integrated systems deliver prescribing functionality natively within an electronic health record, allowing clinicians to create, screen, and transmit prescriptions without leaving the clinical workflow, and this deep embedding is the primary reason for the segment's leadership. With 98% of e-prescribers served by EHR-enabled systems in 2025, the installed base of certified EHRs from vendors such as Epic Systems, Oracle Health, Veradigm, athenahealth, NextGen Healthcare, and eClinicalWorks provides a vast, ready channel for integrated prescribing. Integration enables comprehensive medication history, automated allergy and interaction checks, real-time prescription benefits, and electronic prior authorization to draw on the same patient record, improving safety and efficiency. Regulatory compliance is also more readily achieved within integrated platforms, which build EPCS identity proofing and two-factor authentication into the certified workflow. Vendors reinforce the segment through continuous feature expansion, including Veradigm's network architecture for independent practices and DrFirst's integrations that embed adherence and prior authorization tools into EHR prescribing. The combination of workflow efficiency, safety, compliance, and recurring transaction economics sustains the leadership of integrated systems across the forecast period, while standalone e-prescribing systems continue to serve practices seeking lightweight or EHR-agnostic prescribing.

By Delivery Mode

Dominant Subsegment: Cloud-based.

The cloud-based segment accounted for 74% of the E-Prescribing market in 2025. Cloud-based delivery has become the default deployment model because it minimizes upfront infrastructure investment, accelerates implementation, and simplifies the continuous updates required to stay current with EPCS mandates, formulary changes, and security standards. Web-based platforms allow prescribers to access prescribing functionality from any location and device, a capability that has become essential with the growth of telehealth and distributed care. Cloud architectures also enable rapid integration through application programming interfaces, allowing digital health entrants and independent practices to embed prescribing quickly, and they support the scalable delivery of value-added services such as real-time prescription benefit, which reached 1 billion transactions in 2025. Leading vendors, including athenahealth, NextGen Healthcare, RxNT, and DrFirst, deliver prescribing predominantly through cloud and software-as-a-service models, and network operators such as Surescripts provide cloud-based routing and transparency services at national scale. The advantages of lower total cost of ownership, automatic compliance updates, remote accessibility, and API extensibility secure the dominance of cloud-based delivery across the forecast period, while on-premise deployments persist mainly among large health systems with specific security or integration requirements.

By Usage

Dominant Subsegment: Non-controlled Substance E-Prescribing.

The non-controlled substance e-prescribing segment accounted for 81% of the E-Prescribing market in 2025. Non-controlled medications, including the majority of chronic-disease, acute-care, and maintenance therapies, constitute the bulk of prescribing volume, and their electronic transmission has been standard practice since the meaningful use era, giving this segment its leading position. The routine, high-frequency nature of non-controlled prescribing generates the largest share of network transactions and associated value-added services such as benefit checks, medication history, and adherence messaging. While controlled-substance e-prescribing is the faster-growing usage category, propelled by the Medicare Part D EPCS mandate and expanding state requirements that lifted EPCS enablement to 84.4% of e-prescribers in 2025, it still represents a smaller portion of total prescription volume because controlled substances are a limited subset of overall prescribing. Non-controlled prescribing also anchors the platform relationships and recurring economics on which vendors build higher-value services. The combination of dominant volume, established workflows, and the breadth of associated transparency and adherence services sustains the leadership of non-controlled substance e-prescribing across the forecast period, even as EPCS adoption accelerates alongside it.

By End-User

Dominant Subsegment: Office-based Physicians.

The office-based physicians segment accounted for 46% of the E-Prescribing market in 2025. Office-based physicians and ambulatory practices generate the largest share of outpatient prescriptions and were the earliest and most complete adopters of e-prescribing, supported by meaningful use incentives and the broad availability of ambulatory EHRs, which together explain the segment's leadership. The Surescripts network supported 1.39 million active prescribers in 2025, the majority practicing in ambulatory and office-based settings, and vendors such as Veradigm, athenahealth, NextGen Healthcare, eClinicalWorks, RxNT, and CureMD focus heavily on this cohort. Office-based prescribing spans primary care and a wide range of specialties, driving high-frequency, recurring transaction volume and strong uptake of value-added services including real-time prescription benefit and electronic prior authorization. Independent and small practices are increasingly served through cloud and network-architecture offerings that lower cost and complexity. While hospitals and health systems drive substantial inpatient and discharge prescribing and pharmacies anchor the dispensing end of the workflow, office-based physicians retain leadership in 2025 on the strength of outpatient prescription volume and mature ambulatory adoption, with hospital and specialty-pharmacy usage expanding steadily alongside.

E-Prescribing Market Region Analysis

Dominant Region: North America

North America accounted for 48% of the global E-Prescribing market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the maturity of the United States prescribing ecosystem, where a national routing network, near-universal EHR adoption, and the most developed regulatory and reimbursement framework for electronic prescribing converge. Federal and state EPCS mandates, led by the Medicare Part D requirement enforced from January 2023, have driven controlled-substance e-prescribing enablement to 84.4% of e-prescribers, while 98.3% of pharmacies are EPCS-enabled. The Surescripts network supported 1.39 million active prescribers in 2025 and delivered 1 billion real-time prescription benefit transactions, underscoring the scale and depth of adoption. Healthcare infrastructure is advanced, with integrated delivery networks, ambulatory practices, and specialty pharmacies routinely using integrated prescribing. The regulatory environment is supportive, with the Drug Enforcement Administration providing established identity-proofing and authentication standards and the Centers for Medicare and Medicaid Services actively enforcing EPCS compliance, including expansion to long-term care facilities from January 2025. A strong vendor base, including Surescripts, Veradigm, Oracle Health, Epic Systems, athenahealth, NextGen Healthcare, and DrFirst, and sustained investment in prior authorization automation and transparency services further reinforce North America's leadership.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the E-Prescribing market. The region's elevated CAGR is driven by rapid digitization of healthcare, expanding electronic health record adoption, and growing government support for electronic prescribing across China, Japan, India, South Korea, and Australia. National digital health initiatives and electronic prescription programs are formalizing e-prescribing standards and encouraging adoption in both public and private care. Rising healthcare expenditure, a large and aging patient population, and the expansion of telehealth are increasing prescription volumes and the need for safe, efficient prescribing. Domestic health technology vendors and international entrants are scaling cloud-based platforms tailored to local regulatory and language requirements, while improving pharmacy connectivity broadens network reach. Growing awareness of medication safety and efforts to curb prescription errors and misuse are further encouraging governments and providers to invest in electronic prescribing, positioning Asia-Pacific as the highest-growth region over the forecast period.

E-Prescribing Market Regional Commentary

North America

North America accounted for 48% of the global E-Prescribing market revenue in 2025. The United States dominates the region on the strength of its national routing network, near-universal EHR adoption, and EPCS mandate enforcement, while Canada advances through provincial e-prescribing programs such as national digital prescription services, and Mexico expands electronic prescribing within its growing private healthcare and pharmacy sectors.

Europe

Europe represents the second-largest regional market, led by Germany, the United Kingdom, and France. Growth is supported by national electronic prescription rollouts, including Germany's mandatory electronic prescription for statutory health insurance and the established Electronic Prescription Service in the United Kingdom, alongside cross-border ePrescription frameworks that are standardizing digital prescribing across member states.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by healthcare digitization, expanding EHR adoption, and government electronic prescription initiatives across China, Japan, India, South Korea, and Australia. Rising telehealth use, large patient populations, and domestic platform development are broadening access to cost-effective electronic prescribing beyond major urban centers.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Rising healthcare investment, national digital health strategies, and improving pharmacy and internet infrastructure are expanding access to electronic prescribing, while public and private initiatives increasingly prioritize medication safety and prescription digitization.

E-Prescribing Market Competitive Landscape

The E-Prescribing market is classified as Moderately Concentrated. Prescription routing and network transactions are highly concentrated around a national network operator, Surescripts, which connects the majority of prescribers and pharmacies, while the prescriber-facing software layer is more distributed across a competitive field of electronic health record and dedicated e-prescribing vendors, including Veradigm, Oracle Health, Epic Systems, athenahealth, NextGen Healthcare, DrFirst, eClinicalWorks, RxNT, and CureMD. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately Concentrated, with a consolidated network and transaction layer alongside a more fragmented, competitive software and EHR layer.
• Leading players: Surescripts, Veradigm, Oracle Health, Epic Systems, athenahealth, NextGen Healthcare, and DrFirst anchor the top tier.
• Geographic reach: Leaders operate nationwide United States networks, with selective expansion and localization across Europe, Asia-Pacific, and emerging markets.
• Product portfolio strength: Top players offer integrated portfolios spanning EHR, e-prescribing, EPCS, real-time benefit, prior authorization, and medication adherence.
• Pipeline strength: Active development in artificial-intelligence-driven prior authorization, price transparency, specialty medication management, and adherence tools.
• Strategic partnerships: Collaborations among EHR vendors, digital health platforms, pharmacies, and payers extend reach and embed prescribing into new channels.
• M&A activity: Consolidation continues across prior authorization, medication management, and prescribing infrastructure, exemplified by DrFirst's acquisition of Myndshft.
• Manufacturing and infrastructure capabilities: Network scale, uptime, and security of prescription routing constitute a key competitive moat and a systemic risk.
• Innovation focus: Automation of prior authorization, point-of-care price transparency, EPCS compliance, and artificial-intelligence-assisted prescribing workflows.

E-Prescribing Market Recent Developmental Activities

• In August 2026, DrFirst, Inc. announced that its artificial-intelligence solution fully populates 63% of prior authorizations for prescriptions across its platform with no clinician edits. Strategic significance: Demonstrates the maturation of AI-driven prior authorization automation, reducing administrative burden and therapy delays and strengthening the value of intelligent e-prescribing workflows.
• In August 2026, DrFirst, Inc. received Frost and Sullivan's 2026 North America Enabling Technology Leadership recognition for AI-enhanced medication orchestration. Strategic significance: Validates DrFirst's positioning in intelligent medication management and reinforces competitive differentiation in the prescribing infrastructure market.
• In June 2026, DrFirst, Inc. partnered with Elation Health to support patient medication adherence and therapy initiation. Strategic significance: Extends e-prescribing value into primary care adherence workflows and broadens DrFirst's reach among independent and primary care practices.
• In March 2026, DrFirst, Inc. released its next-generation RxInform solution, driving 30% more patient interactions for medication adherence. Strategic significance: Deepens the shift from transactional prescribing to engagement-driven adherence, adding recurring value beyond core transmission.
• In January 2025, the Centers for Medicare and Medicaid Services extended EPCS compliance actions to prescriptions written for beneficiaries in long-term care facilities. Strategic significance: Broadens the regulatory mandate to a new care setting, expanding the addressable base for compliant controlled-substance e-prescribing.
• In September 2024, ContinuumCloud partnered with DrFirst, Inc. to enhance prescribing workflows and patient safety for behavioral health providers. Strategic significance: Expands e-prescribing and EPCS into behavioral health, a high-need setting for controlled-substance safeguards and monitoring integration.
• In July 2024, CareCloud, Inc. partnered with DrFirst, Inc. to enhance medication adherence and reduce healthcare costs. Strategic significance: Embeds adherence and prescribing intelligence within an ambulatory technology platform, extending value-added services to independent practices.
• In June 2024, Bizmatics partnered with DrFirst, Inc. to add RxInform automated patient messaging to the e-prescribing workflow. Strategic significance: Illustrates the trend of layering patient engagement and adherence tools onto core prescribing to improve outcomes and platform stickiness.
• In April 2024, DrFirst, Inc. acquired Myndshft Technologies to unify pharmacy and medical benefit prior authorization for specialty medications. Strategic significance: Consolidates prior authorization capability for high-value specialty drugs, positioning DrFirst across both benefit types and accelerating specialty medication access.
• In 2024, Veradigm Inc. launched its Health Network Architecture to level the playing field for independent practices. Strategic significance: Strengthens Veradigm's network and prescribing proposition for independent providers, expanding its footprint in the ambulatory segment.
• In January 2023, the Centers for Medicare and Medicaid Services began enforcing the Medicare Part D EPCS mandate, requiring at least 70% of qualifying controlled-substance claims to be transmitted electronically. Strategic significance: Establishes durable regulatory demand for compliant EPCS-enabled platforms and accelerates controlled-substance e-prescribing adoption nationwide.
• In 2025, Surescripts, LLC reported 1.39 million active prescribers, 1 billion real-time prescription benefit transactions, and 84.4% EPCS enablement in its Annual Impact Report. Strategic significance: Confirms the scale and depth of e-prescribing adoption and the growing role of transparency and prior authorization services in the prescribing ecosystem.

E-Prescribing Market Segmentation

• E-Prescribing Market by Product
  • Integrated E-Prescribing Systems
  • Standalone E-Prescribing Systems
• E-Prescribing Market by Delivery Mode
  • Cloud-based / Web-based
  • On-premise
• E-Prescribing Market by Usage
  • Non-controlled Substance E-Prescribing
  • Controlled Substance E-Prescribing (EPCS)
• E-Prescribing Market by End-User
  • Office-based Physicians
  • Hospitals
  • Pharmacies
  • Others

E-Prescribing Market Assessment by Geography

• North America E-Prescribing Market Assessment
  • United States E-Prescribing Market Size in USD million (2023-2034)
  • Canada E-Prescribing Market Size in USD million (2023-2034)
  • Mexico E-Prescribing Market Size in USD million (2023-2034)
• Europe E-Prescribing Market Assessment
  • Germany E-Prescribing Market Size in USD million (2023-2034)
  • United Kingdom E-Prescribing Market Size in USD million (2023-2034)
  • France E-Prescribing Market Size in USD million (2023-2034)
  • Italy E-Prescribing Market Size in USD million (2023-2034)
  • Spain E-Prescribing Market Size in USD million (2023-2034)
  • Rest of Europe E-Prescribing Market Size in USD million (2023-2034)
• Asia-Pacific E-Prescribing Market Assessment
  • China E-Prescribing Market Size in USD million (2023-2034)
  • Japan E-Prescribing Market Size in USD million (2023-2034)
  • India E-Prescribing Market Size in USD million (2023-2034)
  • Australia E-Prescribing Market Size in USD million (2023-2034)
  • South Korea E-Prescribing Market Size in USD million (2023-2034)
• Rest of Asia-Pacific E-Prescribing Market Size in USD million (2023-2034)
  • Rest of the World (RoW) E-Prescribing Market Assessment
  • Middle East E-Prescribing Market Size in USD million (2023-2034)
  • Africa E-Prescribing Market Size in USD million (2023-2034)
  • South America E-Prescribing Market Size in USD million (2023-2034)

E-Prescribing Market Recent Industry Trends and Milestones (2023-2026):

E-Prescribing Market Startup Funding and Investment Trends

Investment in the E-Prescribing ecosystem has concentrated on developer-first prescribing platforms, embedded prescribing infrastructure, and medication access and adherence technology. The following startups illustrate recent funding activity and technology focus.

Photon Health is scaling a developer-first e-prescribing platform that lets telehealth and digital health companies embed compliant prescribing and EPCS through modern application programming interfaces, while DoseSpot provides embedded e-prescribing infrastructure widely integrated across health technology platforms. Additional capital continues to flow toward prior authorization automation, medication access, and adherence technologies, reflecting investor conviction that the next sources of competitive advantage lie in intelligent, embedded, and value-added prescribing services layered on top of the established routing network. Collectively, these rounds signal sustained investment in lowering the cost and complexity of compliant prescribing, expanding access for digital-first care models, and automating the administrative workflows that surround the prescription.

Key Takeaways from the E-Prescribing Market Report Study

• Market size analysis for the current e-prescribing market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global e-prescribing market.
• Various opportunities available for competitors in the e-prescribing market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current e-prescribing market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for e-prescribing market growth in the future?

Target audience who can benefit from this e-prescribing market report study

• E-Prescribing product and software providers
• Research organizations and consulting companies
• E-Prescribing-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in e-prescribing
• Various end-users who want to know more about the e-prescribing market and the latest technological developments in the e-prescribing market.

Frequently Asked Questions

Q1. What is the growth rate of the E-Prescribing market?

The E-Prescribing market is projected to expand at a CAGR of 12.7% during the forecast period of 2026-2034.

Q2. What is the market size of the E-Prescribing market?

The E-Prescribing market size is estimated at USD 3.28 billion in 2025 and is projected to reach USD 9.65 billion by 2034.

Q3. Which region dominates the E-Prescribing market?

North America dominated the E-Prescribing market with a 48% share of global revenue in 2025, supported by a national prescription routing network, near-universal electronic health record adoption, Drug Enforcement Administration standards for EPCS, and active enforcement of the Medicare Part D EPCS mandate by the Centers for Medicare and Medicaid Services. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the E-Prescribing market?

The principal drivers are federal and state EPCS mandates, led by the Medicare Part D requirement enforced from January 2023; near-universal electronic health record adoption, with 98% of e-prescribers served by enabled EHRs and 1.39 million active prescribers on the Surescripts network in 2025; the patient-safety imperative, with the World Health Organization estimating USD 42 billion in annual medication-error costs; and the expansion of real-time prescription benefit and electronic prior authorization services.

Q5. Who are the major players in the E-Prescribing market?

The leading E-Prescribing companies in the market include Surescripts, LLC, Veradigm Inc., Oracle Corporation (Oracle Health), Epic Systems Corporation, athenahealth, Inc., NextGen Healthcare, Inc., DrFirst, Inc., eClinicalWorks, LLC, RxNT, and CureMD Healthcare, among other active software vendors, network operators, and solution providers profiled in the Competitive Landscape section. Surescripts leads prescription routing, while a competitive field of EHR and dedicated e-prescribing vendors serves the prescriber-facing software layer.